HCQ ineffective against mild Covid-19: A randomized trial pu
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Yet another randomized trial found no clinical benefit for hydroxychloroquine (HCQ) in COVID-19, this time in outpatients with early, mild symptoms.

This study aimed to investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients. A Randomized, double-blind, placebo-controlled trial was conducted from 22 March through 20 May 2020.

Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset participated in the study. Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo were administered.

- Of 491 patients randomly assigned to a group, 423 contributed primary end point data.
- Of these, 341 had laboratory-confirmed infection with SARS-CoV-2 or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% were enrolled within 1 day of symptoms starting.
- Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups.
- At 14 days, 24% of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% receiving placebo.
- Medication adverse effects occurred in 43% of participants receiving hydroxychloroquine versus 22% receiving placebo.
- With placebo, 10 hospitalizations occurred, including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death.

Conclusively, Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19.

Source: https://www.acpjournals.org/doi/10.7326/M20-4207
Dr. T●●●●z H●●●●●●i and 7 others like this12 shares